Updated:
Silexion Therapeutics Corp
Silexion Therapeutics Corp is a clinical-stage biotech firm developing RNAi therapies for KRAS-mutated cancers, publicly traded as NASDAQ: SLXN.
Silexion Therapeutics Corp
Silexion Therapeutics Corp is a publicly traded biotechnology firm (NASDAQ: SLXN) specializing in RNAi therapies for solid tumors, particularly those driven by KRAS mutations, a common oncogenic driver in pancreatic, lung, and colorectal cancers. The company was founded in 2006 and is headquartered in Rehovot, Israel, with additional operations in London, UK, and a subsidiary in New York, USA, per public filings. Its lead candidate, SLX-100, targets KRAS G12D mutations, while a second candidate targets G12V. The company's strategy centers on proprietary RNAi technology to silence mutant KRAS expression, an approach that differs from small-molecule inhibitors such as sotorasib. Silexion has advanced through preclinical studies and early-phase clinical trials, reporting interim data from a Phase 2a trial for pancreatic cancer in 2024, per company press releases. The firm collaborates with contract research organizations for manufacturing and clinical work, and its pipeline includes programs for other KRAS variants. As a publicly traded entity, Silexion Therapeutics Corp is not structured as a traditional family office or asset manager but as a biotech corporation with a board of directors and executive management. The company has not disclosed a substantial institutional investment arm, nor does it operate a family-office structure under the same name. Silexion's structural differentiator is its focus on RNAi therapeutics for a well-defined oncogenic target, a space dominated by large pharma but with few clinical-stage RNAi entrants addressing KRAS. This narrow focus contrasts with diversified biotech investment vehicles typical of family offices.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What is Silexion Therapeutics Corp's primary therapeutic focus?
Silexion develops RNAi therapeutics targeting KRAS mutations, notably the G12D and G12V subtypes, which are common in pancreatic, lung, and colorectal cancers. Its lead candidate, SLX-100, has completed Phase 2a trials for pancreatic cancer, per company filings.
Is Silexion Therapeutics Corp a family office or investment firm?
No. Silexion is a publicly traded biotechnology company (NASDAQ: SLXN), not a family office, asset manager, or investment fund. Its business operations focus on drug development, not capital allocation across asset classes.
What are the key milestones in Silexion's development pipeline?
Silexion advanced SLX-100 from preclinical to Phase 2a for pancreatic cancer by 2024, and reported interim data showing manageable safety and potential efficacy, per a 2024 company press release. Further clinical development phases are ongoing.
Where does Silexion Therapeutics Corp operate?
The company is headquartered in Rehovot, Israel, with a UK office in London and a New York subsidiary for regulatory and business development. Its clinical trials are conducted globally through partnerships with CROs, per public filings.
What is Silexion's technological approach?
Silexion uses RNA interference (RNAi) to silence oncogenic KRAS mutations at the mRNA level. This differs from small-molecule drugs that inhibit mutant KRAS protein activity. The company's platform enables targeting of multiple KRAS variants via synthetic siRNA molecules.
Who are Silexion's competitors?
Silexion competes with KRAS-targeting small-molecule drugs like Amgen's sotorasib and Mirati's adagrasib, as well as other RNAi companies such as Alnylam and Dicerna (part of Novo Nordisk). However, Silexion is among the few clinical-stage RNAi firms specifically addressing KRAS G12D/G12V.
What is the corporate history of Silexion Therapeutics Corp?
Founded in 2006, Silexion initially focused on RNAi therapies for cancer. It went public on the Nasdaq via a merger with a SPAC in 2022, trading under the ticker SLXN. The company has since concentrated on advancing its lead candidate into clinical trials, per SEC filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: